|
| |
Overview
Financial Highlight
HeadlinesBusiness Background CCM Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures and markets generic and over-the-counter pharmaceutical products. Its segment is engaged in manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines. The company's products include tablets, capsules, syrup, oral antibiotic, creams, hemodialysis solution, sterile irrigation solution, sterile powder injectables, small volume injectables, dental cartridges and eye drop preparations.
  chandra54 going to fly soon. more orders pouring in from govt pharm. and overseas!grab now! 14/08/2018 16:23 moneytrail Flying back to 1.50? Should be one of the billion market capitalization companies!! 15/08/2018 11:24 jibbie https://www.malaymail.com/s/1662860/ministry-of-health-halts-programme-providing-new-drugs-for-free Is ccmdbio affected by this ruling? 16/08/2018 10:50 moneytrail http://www.theedgemarkets.com/article/clarity-needed-policies-healthcare-industry http://www.theedgemarkets.com/article/ccmd-eyes-strategic-investments 23/08/2018 14:04 thor85 Next week qr result will be good. Early this year moh payment got problems bcoz of govt epayment system mistake. In second quarter the problem is fully solved already.Plus the new product flavettes effervescent glow is very hot in market. 25/08/2018 07:38 Investeye Q2Q is slightly better (but lower compared previous Q). Today share price up 7% already, so further up is just a ?.. Overall it is still reasonable. 27/08/2018 20:41 Romyzam On board. Need to go back 1.27 for uptrend. Cheap at current price. Today forced selling that's y can get low price. Let's see tomorrow. 13/09/2018 17:40 chandra54 yeah romyzam, will go hopless yet again. forget to smell 1.27. this prise is history 18/09/2018 13:03 Romyzam Nice recovery today. More to come tomorrow. Really hope back to 1.27 and above... 19/09/2018 18:28 Romyzam Cool Chandra. Now accumulation time. I bought total 100k shares from 1.15 to 1.19. If break 1.14 again then cut lo 25/09/2018 11:58 Romyzam Sold back all 1.23 to 1.26. Good luck those still holding. Good counter but too slow. Thanks ccmdbio for the quick bucks. 02/10/2018 19:14 Investeye Take opportunity to accumulate more based on EPF kept accumulating recently. In fact after holding some lots for 1.5 yrs, it is still gaining at this price ( due to bonus 4:3 issuing 15 maths ago) 03/10/2018 20:24 moneytrail Collect for long term, consistent profit this 2 years. Factory expansion to bear fruit 2020. Niche product and stem cells product, hope to give higher margin to offset margin erosion from competitive generic drugs. 03/11/2018 15:46  necro I must said recent acquisition & ventures were uninteresting to investor, too many drug & substances in pipeline. Investor dont understand of what is the drug is going to do with Malaysia market. Asean is not like Singapore, Japan or Korea where the country spend 7% of GDP for healthcare budget, Malaysia for example is only use of 3% GDP for healthcare budget. Malaysia healthcare priority budgeting only for "3 serangkai" diseases which diabetes, high blood pressure & heart diseases. Disease like autoimmune, chronic kidney disease(ckd), obstetric &, gynaecology using advance medication were too expensive for government to used. Hopefully CEO does not to eager to pursuing pipeline quantity but focus more on quality, he must realise that that CCMDBIO is conglomerates not science lab where he can test new drug or substances onto Malaysian people. 22/11/2018 09:55 Investeye CCM Duopharma Biotech Bhd’s fourth quarter net profit rose 18.45% to RM14.37 million from RM12.13 million a year ago, due to higher revenue and changes in accounting policies arising from adoption of the Malaysian Financial Reporting Standards 9 (MFRS 9). Earnings per share for the quarter ended Dec 31, 2018 rose to 2.17 sen from 1.86 sen. Quarterly revenue was up 3.01% to RM115.63 million, from RM112.25 million previously, the group said in a filing with Bursa Malaysia. CCM Duopharma has declared a final dividend of four sen, bringing total payout for FY18 to 5.5 sen, as against 3.64 sen in FY17. The group has also proposed that the dividend reinvestment plan would apply to the final dividend. For FY18 as a whole, CCM Duopharma’s net profit increased 12.19% to RM47.64 million or 7.26 sen per share from RM42.46 million or 6.52 sen per share last year, while revenue grew 6.57% to RM498.72 million from RM467.99 million. On prospects, the group said it sees opportunities from the increase in allocation for health services to RM29 billion in Budget 2019 including RM10.8 billion to restore clinics and hospitals as well to buy medicine and medical equipment. “The group will also continue its foray into the specialty products as one of its strategies moving forward to create a pool of niche products,” said CCM Duopharma, adding that it has recently received registration approval for Erysaa, an erythropoeitin product. Barring any unforeseen circumstances, the group expects to achieve satisfactory results in FY19. 18/02/2019 22:08 shpg22 Liquidity has deteriorated quite rapidly, still able to give 4cents dividend. Good management 18/02/2019 22:49  |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
